A synthetic analogue of GLP-1, a hormone the gut releases after eating. It is chemically modified so that it binds to albumin in the blood, which protects it from rapid breakdown and extends its duration from roughly two minutes to about a week.

How does semaglutide differ from Tirzepatide and Retatrutide?

By the number of receptors involved. Semaglutide acts on GLP-1 alone. Tirzepatide is a dual agonist adding GIP. Retatrutide is a triple agonist adding glucagon. Semaglutide has the most mature evidence base of the three; Retatrutide remains investigational.

Why does GLP-1 only work when blood sugar is high?

Because its effect on insulin release is glucose-dependent — the signal fires when glucose is elevated and stays quiet when it is not, more like a thermostat than a switch. This behaviour distinguishes the mechanism from simply supplying additional insulin.

Are Ozempic, Wegovy and Rybelsus the same thing?

They are the same molecule under different brand names and formulations. Ozempic is the injectable approved for type 2 diabetes in 2017, Wegovy the formulation approved for weight management in 2021, and Rybelsus the oral form approved for diabetes in 2019. An oral weight-management formulation was approved in December 2025.

Research Library›Metabolic Research›Semaglutide

GLP-1 Receptor Agonist

Semaglutide: The Compound That Reset the Metabolic Field

The single GLP-1 agonist every newer metabolic compound is measured against. Understanding what it does — and what it does not do — is the starting point for reading anything in this category.

9 min read·6 studies cited·Updated July 2026

Evidence level

Approved as a medicine in at least one jurisdiction

What this level means

Quick Reference

Class	GLP-1 receptor agonist (single agonist)
Developer	Novo Nordisk
Brand names	Ozempic, Wegovy, Rybelsus
First FDA approval	2017 (type 2 diabetes)
Weight indication	2021

What Is Semaglutide?

Semaglutide is a synthetic analogue of GLP-1 — glucagon-like peptide-1, a hormone your gut releases after you eat. It is the compound that turned this whole category from a diabetes niche into the most closely watched area in metabolic medicine, and it remains the reference point against which Tirzepatide, Retatrutide and everything after them is compared.

Natural GLP-1 has one practical problem: the body destroys it within about two minutes. An enzyme called DPP-4 cuts it apart almost immediately. Semaglutide is that same signal, chemically modified to survive — a fatty acid chain attached to the molecule lets it bind to albumin in the blood, sheltering it from breakdown and extending its life from minutes to about a week.

The modification, in plain language: imagine posting a letter that dissolves in the rain. The message is fine — the delivery is the problem. Semaglutide is the same letter in a waterproof envelope. Nothing about the instruction changed; it simply survives the journey. That single engineering fix, turning a two-minute signal into a week-long one, is most of why this compound worked where earlier attempts did not.

What GLP-1 Actually Does

GLP-1 receptors sit in several places, and the compound acts on all of them at once — which is why its effects read as a cluster rather than a single action.

In the pancreas, GLP-1 enhances insulin release, but only when blood glucose is already elevated. That glucose-dependence matters: the signal is conditional rather than constant, which is a meaningfully different behaviour from insulin itself.

In the stomach, it slows gastric emptying — food leaves more slowly, so fullness persists.

In the brain, it acts on appetite-regulating regions in the hypothalamus and hindbrain, and this is where most of the appetite effect originates. It is a signalling change, not a stimulant effect.

Glucose-dependence, in plain language: think of a thermostat rather than a switch. A switch turns the heating on and leaves it on regardless of the room. A thermostat only fires when the temperature actually drops. GLP-1 prompts insulin release when glucose is high and stays quiet when it is not — which is why the mechanism behaves differently from simply adding more insulin to the system.

Why the appetite effect surprised people. When GLP-1 compounds were first developed, the target was blood glucose — this was diabetes research, and weight change was noted as a secondary observation. It took years for the field to recognise that the appetite effect was substantial in its own right, and the weight-management indications followed the diabetes ones by several years in every case. That sequence explains a great deal about how the category is structured: the diabetes trials came first, the obesity trials were built on them, and the cardiovascular outcome data came later still.

Where the effect actually happens. It would be easy to assume the appetite change is a stomach effect, since gastric emptying slows. The published work points mostly elsewhere — to receptors in the hypothalamus and hindbrain, regions that govern how hungry you feel rather than how full your stomach is. The slowed emptying contributes, but the primary action is a change in signalling to the brain. This distinction matters for reading the literature, because it is why the effect is described as altering appetite rather than restricting intake mechanically.

The Evidence Base

Semaglutide has the deepest published record of any compound in this category, and that depth is the main reason it functions as the field’s reference standard.

The SUSTAIN programme established its effects in type 2 diabetes, leading to FDA approval in 2017 (as Ozempic). SUSTAIN-6 additionally reported cardiovascular outcome data — significant, because showing an effect on cardiovascular events is a far higher bar than showing an effect on glucose.

The STEP programme examined weight management, with STEP-1 reporting around 15% mean body-weight reduction at 68 weeks. That led to approval for weight management in 2021 (as Wegovy). An oral formulation, Rybelsus, was approved for diabetes in 2019, and an oral weight-management formulation followed in December 2025.

The SELECT trial then examined cardiovascular outcomes in people with obesity but without diabetes — extending the evidence beyond the original diabetes population.

For context on how the newer compounds relate to it: Tirzepatide added a second receptor (GIP) and reported roughly 22.5% at 72 weeks in SURMOUNT-1; Retatrutide added a third (glucagon) and reported roughly 24.2% at 48 weeks in its Phase 2. Both are measured against semaglutide precisely because semaglutide came first and its data is the most mature.

What It Does Not Do

The most useful thing to understand about semaglutide is the boundary of its mechanism, because that boundary is what the next generation of compounds was built to address.

It acts almost entirely on the intake side of energy balance — appetite, satiety, gastric emptying, insulin response. It does not meaningfully increase energy expenditure. This is the specific gap Retatrutide’s glucagon receptor was added to address, and it is the clearest structural difference between a single agonist and a triple one.

The published literature also documents that weight tends to return following discontinuation, which is consistent with the mechanism: the effect holds while the signal is present. That is a property of signalling compounds generally, and it is a large part of why researchers distinguish them from compounds proposed to act at the level of gene expression.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England journal of medicine, 2021. PubMed
Marso SP, Bain SC, Consoli A, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England journal of medicine, 2016. PubMed
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” The New England journal of medicine, 2023. PubMed
Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in endocrinology, 2019. PubMed
Frías JP, Davies MJ, Rosenstock J, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” The New England journal of medicine, 2021. PubMed
Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell metabolism, 2018. PubMed